Metabolic and Gut Health

Metabolic problems do not always cause noticeable symptoms. Some people experience changes in energy or appetite, while others first learn about a concern through routine blood work or other clinical findings.

Yes. Metabolic concerns such as insulin resistance can occur across a wide range of body weights. Evaluation looks beyond the scale to the broader clinical picture, including relevant testing and other risk factors.

Insulin resistance means that cells do not respond to insulin as effectively as they should. The pancreas may compensate by producing more insulin. Over time, blood glucose can rise and progress to prediabetes or type 2 diabetes in some people (2).

Researchers do not attribute insulin resistance to one universal cause. Genetics, physical inactivity, excess adiposity, some medications, sleep patterns, and certain medical conditions can all contribute to risk (2).

Insulin resistance can improve substantially in many people. Improving sleep, movement, and nutrition may support better insulin sensitivity, with weight reduction or medical treatment added when appropriate. Some patients also require medication.

“Reversed” should not be interpreted as a guaranteed permanent cure, and ongoing monitoring may still be appropriate.

Research suggests that gut microbes and the compounds they produce may interact with glucose metabolism, intestinal-barrier function, and inflammatory pathways. Scientists are actively studying these relationships, but microbiome changes do not explain every case of insulin resistance (1).

The gut microbiome is the community of microorganisms and their genetic material within the gastrointestinal tract. These organisms interact with food, the intestinal environment, and immune pathways. Researchers continue to study their roles in digestive and metabolic health.

SIBO stands for small intestinal bacterial overgrowth. It can be associated with bloating, abdominal discomfort, diarrhea, or constipation. Because these symptoms have many possible causes, SIBO should not be diagnosed on symptoms alone.

“Leaky gut” is a common term for increased intestinal permeability. Changes in intestinal-barrier function occur in recognized medical conditions, but “leaky gut syndrome” is not an established explanation for every digestive or systemic symptom.

IBS involves recurring abdominal symptoms and bowel changes without the visible intestinal damage seen in inflammatory bowel disease. Crohn’s disease and ulcerative colitis are inflammatory bowel diseases that can cause intestinal inflammation and may require ongoing specialist treatment (5).

Stress can influence gastrointestinal motility, appetite, eating patterns, and sleep. Stress hormones also participate in glucose regulation. Persistent symptoms or abnormal glucose findings should still be medically evaluated rather than attributed to stress alone.

Sleep patterns can influence metabolic regulation, particularly when sleep is consistently inadequate or disrupted. Controlled studies have found that sleep disruption can reduce measures of insulin sensitivity, which is one reason sleep may be considered during metabolic evaluation (3).

Hormonal signals can affect how the body uses energy and regulates glucose, with downstream effects on appetite and body composition. Conditions such as PMOS may also involve insulin resistance. Hormone testing should be selected according to symptoms and medical history.

Testing may include fasting glucose, A1C, lipids, and other markers selected according to medical history and risk. Insulin, thyroid markers, nutrient testing, or additional cardiovascular evaluation may also be appropriate for some patients.

No. Digestive evaluation depends on the symptoms and suspected condition. In some cases, standard medical testing may be more useful than stool or microbiome analysis. Routine commercial microbiome testing also has important clinical limitations (6).

Nutrition can affect both digestive function and metabolic health, but the right approach depends on the patient’s condition and overall needs. A single “metabolic diet” is not appropriate for everyone.

Obesity is a chronic disease associated with biological, environmental, behavioral, and other factors. It can raise the risk of type 2 diabetes and cardiovascular disease. Metabolic health, however, cannot be determined from weight alone.

Weight loss refers specifically to reducing body weight. Weight management takes a longer-term view, with the goal of reaching or maintaining a clinically appropriate weight while supporting metabolic health.

GLP-1 receptor agonists and related medications can be appropriate for some patients with obesity, overweight plus certain health risks, or type 2 diabetes, depending on the medication. Treatment requires individualized medical evaluation and ongoing monitoring.

Pregnancy and postpartum recovery can affect metabolism as hormonal shifts and changes in sleep influence energy and glucose regulation. Previous gestational diabetes or postpartum thyroid changes may also shape metabolic health during this stage. After delivery, systems may take time to recalibrate. Some women notice cravings, energy crashes, or post-pregnancy weight loss resistance.

InBody uses bioelectrical impedance analysis to estimate aspects of body composition, including body fat and lean mass. It can provide information beyond scale weight, although results should be interpreted alongside the broader clinical picture.

Functional medicine looks at metabolic concerns in the context of the broader health picture, including factors that may affect digestion and metabolic regulation. At hol+, that systems-based evaluation is physician-led and used alongside conventional medical assessment.

Yes, as part of appropriate medical diabetes care. Lifestyle changes can support diabetes management, but they do not replace appropriate glucose monitoring or medical treatment.

Some peptide therapies are marketed or used for metabolic purposes, but evidence, regulatory status, and clinical indications vary substantially by product. hol+ may discuss peptide therapy when medically appropriate and available rather than treating peptides as a standard part of metabolic care.